Edward Cabral

ORCID: 0009-0004-2935-4993
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Advanced Breast Cancer Therapies
  • Pancreatic and Hepatic Oncology Research
  • Inflammasome and immune disorders
  • Infrared Thermography in Medicine
  • interferon and immune responses
  • NF-κB Signaling Pathways
  • Lung Cancer Research Studies
  • Cell Adhesion Molecules Research
  • Radiopharmaceutical Chemistry and Applications

Pfizer (United States)
2024-2025

Astellas Pharma (United States)
2016

ImaginAb (United States)
2014-2015

Precise regulation of Type I interferon signaling is crucial for combating infection and cancer while avoiding autoimmunity. negatively regulated by USP18. USP18 cleaves ISG15, an interferon-induced ubiquitin-like modification, via its canonical catalytic function, inhibits receptor activity through scaffold role.

10.1016/j.isci.2024.109593 article EN cc-by-nc iScience 2024-03-27

Abstract A dysregulated cell cycle is a hallmark of cancer and inhibition cyclin dependent kinases (CDKs) proven therapeutic strategy in treating HR+/HER2- breast variety other cancers. 18F-FLT (18F-3'-deoxy-3'-fluorothymidine) validated positron emission tomography (PET) biomarker to measure proliferation. Here we show the utility PET imaging as pharmcodynamic (PD) differentiating efficacy PF-07104091 (CDK2 selective inhibitor) Palbociclib (CDK4/6 sensitive resistant tumor models. was...

10.1158/1535-7163.mct-24-0856 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2025-03-21

Abstract Immune checkpoint inhibitors have shown limited success in breast cancer, the most common and deadly cancer women worldwide. Novel immune therapies like CD3 engaging bispecific antibodies clinical promise hematologic malignancies. However, developing bispecifics for solid tumors has been challenging due to difficulty identifying tumor-specific antigens. B7-H4 is proposed as an attractive tumor-associated antigen therapeutics with comprehensive coverage regardless of molecular...

10.1158/1535-7163.mct-24-0379 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2025-05-14

Positron Emission Tomography (PET) is a molecular imaging modality that can be used to investigate multitude of pharmacological questions, such as biomarker modulation, receptor occupancy, and biodistribution compounds interest. In studies, experimental subjects are often longitudinally imaged after receiving the test article. The images then analyzed derive compound's distribution profile in various organs at different timepoints. This constitutes crucial step drug development understand...

10.3791/67370 article EN Journal of Visualized Experiments 2024-10-25

Abstract Background: Infiltration of CD8+ T cells into human tumors is associated with an increased disease-specific survival in many cancers. A better understanding cell trafficking and characterization the subset highest localized activity would improve ability to schedule select patients for chemo- immuno-therapy regimens. To facilitate this objective, we have engineered a humanized anti-CD8 antibody fragment used it image tumor xenograft mouse model. Methods: The VH VL sequences murine...

10.1158/1538-7445.am2014-lb-163 article EN Cancer Research 2014-10-01
Coming Soon ...